Advice on scheduling of cannabis-derived medicinal products

Advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.


Scheduling of cannabis-derived medicinal products: ACMD response

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


Letter from the ACMD chair, Dr Owen Bowden-Jones, to the Home Secretary Sajid Javid, responding to the commission to consider the appropriate scheduling of cannabis-derived medicinal products.

This follows part 1 of the review conducted by the Chief Medical Officer, which evaluated existing research into the therapeutic and medicinal benefits of cannabis-derived medicinal products.

Published 19 July 2018